Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
GlaxoSmithKline Biologicals s.a. Patents
Assignee:
GlaxoSmithKline Biologicals s.a.
Address:
Rixensart, BE
No. of patents:
60
Patents:


1 2










Patent Number Title Of Patent Date Issued
D485365 Vial January 13, 2004
8580279 Compounds November 12, 2013
The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylacti
8574596 Pertussis antigens and use thereof in vaccination November 5, 2013
The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions
8568733 HER-2/neu fusion proteins October 29, 2013
The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nuclei
8563002 Recombinant RSV antigens October 22, 2013
This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
8232255 Methods for vaccinating against malaria July 31, 2012
The invention pertains to methods for protecting against malaria infection by vaccination. The method of the invention involves priming an anti-malaria immune response with a DNA-based vaccine and boosting that response with a protein-based a vaccine. The method of the invention also
8221770 Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria July 17, 2012
The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of nei
8217159 BASB082 polynucleotides July 10, 2012
The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylacti
8207123 Tumour-specific animal proteins June 26, 2012
CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for
8192747 Live attenuated rotavirus vaccine for oral administration June 5, 2012
This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate, wherein said formulation has a pH o
8173411 Drying process for preserving an active agent as a highly viscous liquid May 8, 2012
The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing a
8163295 Outer membrane vesicles and uses thereof April 24, 2012
The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium.
8137681 Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines March 20, 2012
The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compos
8097257 MAGE3 polypeptides January 17, 2012
The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof.
8084235 Purification process for bacterial cytolysin December 27, 2011
The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in
8044183 Process for the production of immunogenic compositions October 25, 2011
The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.
8034617 Cell culture in culture media free of components of animal origin October 11, 2011
The present invention relates to a process for animal, preferably human, diploid anchorage-dependent cell culture, in the absence of exogenous components of primary animal origin, and to a cell culture medium substantially free of exogenous components of primary animal origin suitabl
8029807 Outer membrane vesicles and uses thereof October 4, 2011
The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium.
7955817 Vaccine protection assay June 7, 2011
The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine
7939084 Vaccine against varicella zoster virus May 10, 2011
Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuva
7927858 Drying process April 19, 2011
The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing a
7858098 Vaccine December 28, 2010
This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV16 and HPV 18 virus like particles provides cross-protection against other HPV types.
7838014 Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB- Neisseri November 23, 2010
The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of nei
7838003 BASB205 polypeptides and polynucleotides from Haemophilus influenzae November 23, 2010
The invention provides BASB205 polypeptides and polynucleotides encoding BASB205 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7815915 Mixture of human papillomavirus virus-like particles October 19, 2010
The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.
7811574 Tumour-specific animal proteins October 12, 2010
CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for
7803379 Tumour-specific animal proteins September 28, 2010
CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for
7790180 Immunogenic composition of a homogeneous live attenuated human rotavirus population September 7, 2010
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavir
7790179 Homogeneous attenuated human rotavirus population September 7, 2010
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavir
7758866 Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 July 20, 2010
An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of the
7754225 Method of protecting against staphylococcal infection July 13, 2010
A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk o
7691395 BASB119 polypeptide and polynucleotide from Moraxella catarrhalis April 6, 2010
The invention provides BASB119 polypeptides and polynucleotides encoding BASB119 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7666988 BASB082 Polypeptides February 23, 2010
The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylacti
7662399 BASB054 polypeptides February 16, 2010
The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic
7641910 BASB027 proteins and genes from Moraxella catarrhalis, antigens, antibodies, and uses January 5, 2010
The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7632516 Moraxella catarrhalis BASB115 polypeptides December 15, 2009
The invention provides BASB115 polypeptides and polynucleotides encoding BASB115 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7628995 Outer membrane vesicles and uses thereof December 8, 2009
The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium.
7612173 Vaccine for prevention and treatment of HIV-infection November 3, 2009
This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24
7592158 BASB019 proteins and genes from Moraxella catarrhalis, antigens, antibodies, and uses September 22, 2009
The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7579008 Immunization with an attenuated human rotavirus August 25, 2009
The invention provides a method of inducing an immune response against rotavirus infection from one rotavirus serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a different serotype. There is in particular provided
7521549 Compounds April 21, 2009
The invention provides BASB041, 43, 44 and 48 polypeptides and polynucleotides encoding BASB041, 43, 44 and 48 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7510698 Vaccines March 31, 2009
The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.
7470782 CASB618 polynucleotides and polypeptides and their use December 30, 2008
CASB618 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB618 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of c
7439320 Cripto tumour polypeptide October 21, 2008
Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptid
7431352 System for providing communication between the interior and the exterior of a compartment October 7, 2008
A system for making a connection between the interior and exterior of a compartment, comprising a door opening through the compartment wall, a connector body which can engage with the wall, and having a connection port through it, and a removable cover on the connector body. The body is
7419824 BASB006 polypeptides from Neisseria meningitidis and immunogenic compositions thereof September 2, 2008
The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7416846 Vaccine composition comprising virus-like particles of human papillomavirus August 26, 2008
The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.
7365343 Apparatus and process for filling a medicament into a container April 29, 2008
Apparatus for introducing a medicament into containers, especially vials, in which the containers are passed through an enclosure and exposed therein to a sterilising electron beam. The containers are then conveyed to a filling station situated outside the enclosure at which a wall part
7291722 Polypeptide from haemophilus influenza November 6, 2007
The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
7252308 Connector device for the sterile connection of tubes August 7, 2007
A connector for forming a sterile connection between two tubes, comprising first and second parts which comprise connectable conduits and which can mate, first and second covers which can be removed from the so-mated parts to expose connectable ends of the first and second conduits, so
1 2

 
 
  Recently Added Patents
Method of purifying crude acetone stream
Image processing apparatus, method, and storage medium for performing soft proof processing
Sliding-type portable communication device
Embedded bonding pad for image sensors
Position-measuring device
Device and method incorporating an improved text input mechanism
Method for combining images and magnetic resonance scanner
  Randomly Featured Patents
Combined container and cap
Ceramic discharge vessel having an opaque zone and method of making same
Speaker apparatus
Folded cross grid dipole antenna
Apparatus and process for separating substances
Method and apparatus for selecting shift points in an automated mechanical transmission
Touch display apparatus and electronic reading apparatus with touch input function
Cermet powder for sprayed coating excellent in build-up resistance and roll having sprayed coating thereon
Semi-continuous magnesium-hydrogen reduction process for manufacturing of hydrogenated, purified titanium powder
Device apt to permit skiing on snowless ground